Cardiff Oncology, Inc. (CRDF) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor. The company is currently advancing onvansertib in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC) and supporting investigator-initiated trials in other indications including pancreatic cancer, small cell lung cancer, and triple-negative breast cancer.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $41 | $109 |
| Net Loss | $(12,345) | $(13,434) |
| Net Loss Per Share (Basic/Diluted) | $(0.18) | $(0.20) |
| Operating Expenses | $12,891 | $14,491 |
| Cash, Cash Equivalents & Short-Term Investments | $46,056 | $58,304 |
| Working Capital | $32,879 | $43,734 |
| Net Cash Used in Operating Activities | $(12,288) | $(12,794) |
Note: Revenue consists entirely of royalty revenues from legacy intellectual property licenses unrelated to onvansertib.
Material Changes vs. Prior Period
- Revenue Decline: Royalty revenues decreased by approximately 62% to $41,000 from $109,000 in Q1 2025, driven by the timing of licensee sales activities.
- Expense Reduction: Total operating expenses decreased by $1.6 million to $12.9 million. Research and Development (R&D) expenses dropped significantly by $3.7 million (to $6.8 million) due to reduced clinical trial and preclinical activity costs.
- SG&A Increase: Selling, General, and Administrative (SG&A) expenses increased by $2.1 million (to $6.1 million). This increase was primarily driven by employee severance agreements and associated stock-based compensation modifications related to the departure of the former CEO and CFO.
- Liquidity Position: Cash and short-term investments decreased by approximately $12.2 million quarter-over-quarter, reflecting the net cash burn from operations partially offset by net investment maturities.
Outlook, Risks, and Management Commentary
- Going Concern Uncertainty: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. As of March 31, 2026, the company had $46.1 million in liquid assets, which is projected to fund operations only into the first quarter of 2027. Additional equity or debt financing is required to meet funding requirements for the next 12 months.
- Clinical Progress: The company completed an End-of-Phase 2 meeting with the FDA and aligned on the design for a Phase 3 registrational trial in first-line RAS-mutated mCRC. Updated data from the CRDF-004 trial showed the 30 mg onvansertib dose achieved a 72.2% objective response rate (ORR) compared to 43.2% for standard of care.
- Leadership Changes: New leadership was appointed in April 2026, including Mani Mohindru as CEO, Josh Muntner as CFO, and Ajay Aggarwal as COO.
- Legal Contingency: The company received a notice from its licensor, Nerviano, alleging a material breach of the license agreement regarding joint ownership of certain patents. The company disputes the claim and is in discussions; however, failure to resolve the dispute could lead to termination of the license, which would have a material adverse effect on the business.
Investor Verification Checklist
- Capital Runway: Verify the timeline for securing additional financing given the "substantial doubt" going concern warning and the projection of funds lasting only into Q1 2027.
- License Dispute: Monitor the status of the dispute with Nerviano regarding patent ownership, as resolution is critical to the commercialization rights of onvansertib.
- Phase 3 Design: Confirm the final design and enrollment timeline for the Phase 3 trial in RAS-mutated mCRC, expected to be shared by mid-2026.
- Severance Impact: Assess the one-time nature of the SG&A increase due to executive severance and the impact on future operating cost structures.